Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Dutch academics identify free radical scavengers/xanthine oxidase inhibitors

Sep. 10, 1998

Taisho and Nihon Nohyaku describe development of potential new antipsychotics at ACS meeting

Sep. 9, 1998

Fujisawa prepares new urea derivatives as 5-HT antagonists

Sep. 9, 1998

Vanguard Medica, Roche to collaborate on development of endothelin antagonist

Sep. 9, 1998

Schwarz to market rectal morphine product developed by Core

Sep. 8, 1998

Lilly's mGlu agonists exert neuroprotective effects in vivo

Sep. 8, 1998

Lilly research leads to dual tachykinin antagonists/5-HT agonists

Sep. 8, 1998

Licensing opportunity from NIH: method of inducing increased resistance to stroke

Sep. 8, 1998

CP-154526, a CRF1 receptor antagonist, reduces stress-induced relapse of drug use in rats

Sep. 8, 1998

Lilly and Synaptic enter late-stage trials with antimigraine agent

Sep. 7, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...